# US 2021/0330863 A1 · 5-hydroxytryptamine 1b receptor-stimulating agent for enhancing in vivo engraftment potential

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330863 A1
- Document ID: US20210330863A1
- Status: Published application
- Kind: A1
- Application number: 17/329,079
- Filed: 2021-05-24
- Published: 2021-10-28
- Earliest claimed: 2015-11-20
- Assignees: Institut Pasteur; Universite Paris Descartes; Centre Hospitalier Sainte Anne Paris
- Applicants: Institut Pasteur; Universite Paris Descartes; Centre Hospitalier Sainte Anne Paris
- Inventors: Fabrice Bruno CHRETIEN; Raphael GAILLARD; Pierre ROCHETEAU
- Web page: https://patentgrep.com/patent/US20210330863A1

## CPC

- A61L 27/3687: {characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents}
- A61K 31/138: Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377)
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/499: Spiro-condensed pyrazines or piperazines
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 35/12: Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00)
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61P 25/06: Antimigraine agents
- A61P 25/24: Antidepressants
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61L 2430/02: for reconstruction of bones; weight-bearing implants
- A61L 2430/30: for muscle reconstruction
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to the field of regenerative medicine, and more particularly to the improvement of the in vivo engraftment potential of biological material to be administered to a subject in need thereof.

## Claims

### Claim 1

A method for enhancing the in vivo engraftment potential of a biological material, comprising at least the step of in vitro and/or ex vivo contacting an isolated biological material with at least one 5-hydroxytryptamine 1B receptor (5-HT1 BR)-stimulating agent.

### Claim 2 (depends on 1)

The method according to claim 1, wherein said agent is selected from the group consisting of antidepressant agents and antimigraine drugs, pharmaceutically acceptable derivatives, analogs, isomers, metabolites, salts, solvates, clathrates, polymorphs, and co-crystals thereof, and combinations thereof.

### Claim 3 (depends on 2)

The method according to claim 2, wherein said antidepressant agent is selected from the group consisting of atypical antidepressants, preferably bisarylsulfanyl amines such as vortioxetine, and tianeptine, agomelatine, nefazodone, trazodone, buspirone, tandospirone, and ketamine; selective serotonin reuptake inhibitors (SSRIs), preferably fluoxetine, citalopram, escitalopram, sertraline, norsertraline, paroxetine, fluvoxamine, femoxetine, indalpine, alaproclate, cericlamine, ifoxetine, zimelidine, dapoxetine, etoperidone, and metabolites thereof desmethylcitalopram, didesmethylcitalopram, and seproxetine; serotonine and norepinephrine reuptake inhibitors (SNRIs), preferably duloxetine, venlafaxine, desvenlafaxine, milnacipran, levominalcipran, and sibutramine; serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRIs), preferably bicifadine, brasofensine, tesofensine, and nomifensine; tricyclic antidepressants (TCAs), preferably clomipramine, amoxapine, nortriptyline, maprotiline, trimipramine, imipramine, desipramine and protriptyline; monoamine oxidase inhibitors (MAOs), preferably iproniazide, phenelzine, tranylcipromine, moclobemide, selegiline and rasagiline; and noradrenergic and specific serotoninergic antidepressants (NaSSAs), preferably mirtazapine, mianserin, aptazapine, esmirtazapine, setiptiline and S32212 (also known as N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-1,2-dihydro-3H-benzo[e]indole-3-carbo-xamide).

### Claim 4 (depends on 2)

The method according to claim 2, wherein said antimigraine drug is ergotamine or a triptan, said triptan being preferably selected from the group consisting of sumatriptan, rizatriptan, zolmitriptan, eletriptan, almotriptan, frovatriptan, naratriptan avitriptan, and donitriptan.

### Claim 5 (depends on 1, 2, 3, 4)

The method according to any one of claims 1 to 4, wherein said agent is modified to comprise at least one charged chemical moiety, preferably positively charged.

### Claim 6 (depends on 5)

The method according to claim 5, wherein said positively charged chemical moiety is a quaternary ammonium group or a tertiary sulfonium group.

### Claim 7 (depends on 6)

The method according to claim 6, wherein
said quaternary ammonium group has the formula (I)
—(NR1R2R3)+Z− (I)
wherein
Z is an organic or inorganic anion; and
R1, R2 and R3 are each independently selected from the group consisting of alkyl, aryl and cycloalkyl; or
said tertiary sulfonium group has the formula (II)
—(SR4R5)+Z− (II)
wherein
Z is an organic or inorganic anion; and
R4 and R5 are each independently selected from the group consisting of alkyl, aryl and cycloalkyl.

### Claim 8 (depends on 5, 6, 7)

The method according to any one of claims 5 to 7, wherein said agent is a positively charged vortioxetine selected from the group consisting of salts of vortioxetine, vortoxietine coupled to at least one positively charged amino acid such as histidine, arginine or lysine, pyrrolidinium-vortioxetine, pyperazinium-vortioxetine, dimethylammonium-vortioxetine, sulfonium-vortioxetine, N-oxide-vortioxetine, sulfoxide-vortioxetine, and phosphonium-vortioxetine.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method according to any one of claims 1 to 8, wherein said biological material is selected from the group consisting of cells, tissues, organs, derivatives thereof, and combinations thereof.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

An isolated biological material with enhanced in vivo engraftment potential, obtainable according to the method as defined in any one of claims 1 to 9.

### Claim 11 (depends on 10)

A medical device comprising at least the biological material according to claim 10 and optionally at least one pharmaceutically acceptable excipient.

### Claim 12 (depends on 10, 11)

The biological material according to claim 10, or the medical device according to claim 11, further comprising at least one active agent.

### Claim 13 (depends on 10, 11, 12)

An isolated biological material as defined in claim 10 or 12, or a medical device as defined in claim 11 or 12, for use as a medicament.

### Claim 14 (depends on 10, 11, 12)

An isolated biological material as defined in claim 10 or 12, or a medical device as defined claim 11 or 12, for use in a subject in need of cell, tissue or organ regeneration.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

A 5-hydroxytryptamine 1B receptor (5-HT1 BR)-stimulating agent as defined in any one of claims 1 to 8, for a pre-therapeutic use in a subject in need of cell, tissue or organ regeneration.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

A 5-hydroxytryptamine 1B receptor (5-HT1 BR)-stimulating agent as defined in any one of claims 1 to 8, for a pre-therapeutic use in a subject in need of a treatment intended for cell, tissue or organ regeneration, and co- and/or post-therapeutic use in said subject undergoing said treatment.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

A 5-hydroxytryptamine 1B receptor (5-HT1 BR)-stimulating agent as defined in any one of claims 1 to 8, for a co-therapeutic and/or post-therapeutic use in a subject undergoing cell, tissue or organ regeneration.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

An isolated biological material and a 5-hydroxytryptamine 1B receptor (5-HT1 BR)-stimulating agent as defined in any one of claims 1 to 8, as a combined preparation for simultaneous, separate or sequential administration in a treatment intended to regenerate cells, tissues or organs in a subject in need thereof.
